Home>Topics>>Akashi DMD drug candidate Fast Tracked

Akashi DMD drug candidate Fast Tracked

SeekingAlpha.com: SA Currents

Thu, 3 Jul 2014

The FDA grants Fast Track designation to Akashi Therapeutics' lead product candidate HT-100 (delayed-release halofuginone) as a potential treatment to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne Muscular Dystrophy (DMD). The agency has also ...
Content Partners